| アブストラクト | BACKGROUND/AIMS: There are few studies that comprehensively report real-world persistence for first-line advanced therapies used to treat inflammatory bowel disease. We aimed to describe persistence of first-line advanced therapies among incident biologic or Janus kinase inhibitor users with inflammatory bowel disease. METHODS: Retrospective cohort study using the Japan Medical Data Center database from January 1, 2010, until September 30, 2022. Patients aged >/=15 years with relevant diagnostic and treatment codes were included. All eligible patients were observed until study end (September 30, 2022), death, or disenrollment, whichever occurred first. RESULTS: Among 1,115 patients with Crohn's disease included in the analysis, 41.4% initiated adalimumab, 37.4% infliximab, 18.1% ustekinumab, and 3.0% vedolizumab. Median age was 31.2-34.8 years, 72.8% to 85.9% were male. Persistence at 12 months was 84.7% for adalimumab, 87.7% for infliximab, 91.3% for ustekinumab, and 53.1% for vedolizumab. Persistence at 24 months was 76.3%, 76.8%, 80.4%, and 28.6%, respectively. Among 1,942 patients with ulcerative colitis, 24.8% initiated adalimumab, 33.6% infliximab, 11.2% golimumab, 17.5% vedolizumab, 5.6% ustekinumab, and 7.3% tofacitinib. Mean age was 38.2-40.4 years, 57.4% to 65.8% were male. Persistence at 12 months was 57.6% for adalimumab, 87.7% for infliximab, 54.9% for golimumab, 69.7% for vedolizumab, and 84.0% for ustekinumab. At month 24, persistence for ustekinumab was 75.0%, versus 42.9%-59.4% for other treatments. CONCLUSIONS: Index treatment with ustekinumab resulted in high persistence through 24 months after initiation in patients with Crohn's disease or ulcerative colitis. Our study provides insights into the real-world usage of advanced treatments for patients with IBD in Japan. |
|---|
| 投稿者 | Matsuoka, Katsuyoshi; Nakajo, Ko; Kawamura, Shiho; Zhang, Yongjing; Chung, Hsingwen; Wahking, Bryan; Tan, Jin Yu; Qiu, Hong |
|---|
| 組織名 | Division of Gastroenterology and Hepatology, Department of Internal Medicine,;Sakura Medical Center, Toho University, Sakura, Japan.;Office of the Chief Medical Officer, Johnson & Johnson, Tokyo, Japan.;Johnson & Johnson International, Singapore.;Office of the Chief Medical Officer, Johnson & Johnson, Shanghai, China.;Office of the Chief Medical Officer, Johnson & Johnson, Raritan, NJ, USA. |
|---|
